DCF Advisers LLC Invests $2.09 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR

DCF Advisers LLC bought a new position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 30,000 shares of the company’s stock, valued at approximately $2,086,000.

A number of other large investors have also modified their holdings of the business. Aberdeen Group plc lifted its position in Structure Therapeutics by 46.1% during the third quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock worth $16,432,000 after buying an additional 185,245 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in Structure Therapeutics during the third quarter worth approximately $4,770,000. Private Capital Advisors Inc. purchased a new position in Structure Therapeutics during the third quarter worth approximately $1,545,000. Capricorn Fund Managers Ltd purchased a new position in Structure Therapeutics during the fourth quarter worth approximately $17,568,000. Finally, First Light Asset Management LLC lifted its position in Structure Therapeutics by 61.5% during the third quarter. First Light Asset Management LLC now owns 197,350 shares of the company’s stock worth $5,526,000 after buying an additional 75,124 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on GPCR. Wall Street Zen cut shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Citizens Jmp reduced their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. BMO Capital Markets set a $145.00 price objective on shares of Structure Therapeutics and gave the company an “outperform” rating in a report on Tuesday, March 17th. Finally, Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $109.25.

Structure Therapeutics Price Performance

GPCR opened at $41.53 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $15.80 and a 12 month high of $94.90. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of -47.74 and a beta of -1.35. The business has a fifty day moving average price of $43.89 and a 200 day moving average price of $57.21.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.